News | June 17, 2008

PET Identifies Patients Responsive to Non-Hodgkin’s Lymphoma Treatments

June 18, 2008 - Positron emission tomography (PET) could be an important tool for identifying non-Hodgkin’s lymphoma patients who are likely to respond well to treatment with 90 ibritumomab tiuxetan (IT)—the first radioimmunotherapy treatment approved for use by the FDA, said researchers at SNM’s 55th Annual Meeting.

PET imaging allows practitioners to identify patients who could be treated, predict how they would respond and identify relapses early in patients who have follicular lymphoma, a common type of slow-growing lymphoma.

“This study illustrates how PET could be used to advance the goal of personalized medicine—identifying and targeting the right treatment for each individual,” said Stefano Fanti, professor of nuclear medicine at the Policlinico S. Orsola–Università di Bologna in Bologna, Italy, and a researcher of this study. “The functional data provided by PET are essential for determining stages of cancer, detecting disease relapses and evaluating how patients respond to particular therapies. Our study clearly indicates that the next step—using PET for predicting how patients will respond to treatment—can be achieved.”

In the United States, about 65,000 new cases of non-Hodgkin’s lymphoma are diagnosed every year. The number of new cases is on the rise, especially among older people and people whose immune systems are not functioning normally. Those at risk include people who have had organ transplants and those with human immunodeficiency virus (HIV).

Non-Hodgkin's lymphomas are a diverse group of cancers that develop in B or T lymphocytes, which are white blood cells that normally defend the body against bacteria and other pathogens. This group of cancers is actually the cause of more than 20 diseases, which have distinct appearances under the microscope and different clinical courses. Most non-Hodgkin's lymphomas are from B cells.

IT is a monoclonal antibody used in conjunction with radioactive medications to treat non-Hodgkin’s lymphoma patients who have relapsed after treatment or for those with slow-growing forms of the disease such as follicular lymphoma. While there have been studies to investigate the usefulness of PET in patients with lymphoma and research into the effectiveness of radioimmunotherapy, no data were available regarding the role of PET in determining whether patients would be good candidates for IT.

In their study, Fanti and his team examined 38 non-Hodgkin’s lymphoma patients who were treated with IT after a relapse. PET scans were taken before IT treatment and then three months after treatment began. All patients had a final assessment at six months using clinical data.

Results indicated that the first set of PET scans detected the relapse and extent of the disease in all of the patients. At the six-month follow up, 89 percent of the patients were either in complete or partial remission after the IT treatment. Comparison of PET data on the extent of patients’ disease at relapse and their response after three months indicated a higher rate of response to the treatment in patients whose cancer was limited. In all of the cases, the findings of the PET scans at three months were consistent with the clinical findings at six months.

Scientific Paper 584: P. Castellucci, G. Montini, I. Santi, V. Ambrosini, R. Franchi, S. Fanti, Nuclear Medicine, Policlinico S. Orsola, Bologna, Italy; P. Zinzani, M. Tani, V. Stefoni, Haematology, Policlinico S. Orsola, Bologna, Italy; D. Rubello, Ospedale S. Maria della Misericordia, Rovigo, Italy; “FDG-PET in the Assessment of Patients with non-Hodgkin’s Lymphoma Treated by Ibritumomab Tiuxetan,” SNM’s 55th Annual Meeting, June 14–18, 2008.

For more information: www.snm.org

Related Content

FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
PET Imaging Shows Protein Clumping May Contribute to Heart Failure Development
News | PET Imaging | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
Novel PET Agent Could Help Guide Therapy for Brain Diseases

Rat brain 11C‐Me‐NB1 PET images (0‐60 min) superimposed on an MRI template. Credit: SD Krämer et al., ETH Zurich, Zurich, Switzerland

News | PET Imaging | April 10, 2018
Researchers have developed a new imaging agent that could help guide and assess treatments for people with various...
Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
Overlay Init